Clinical Trial to Evaluate the Efficacy and Safety of Platelet-rich Plasma Infiltration in Chronic Omalgia

NCT07448285 | Recruiting Phase 3

• 1 other identifier: SHIELD-PRP
• Study Type: interventional
• Target: 86
• Locations: 1 country
• Sites: 2

Brief Summary

The experimental group will receive intralesional injections of platelet-rich plasma, evaluating its ability to relieve pain and provide sustained improvement through biological modulation of the joint and tendon environment. In contrast, the control group will be treated with a combination of betamethasone and ropivacaine, representing the current standard of care for short-term inflammatory pain management. The comparison between these two options will determine whether platelet-rich plasma offers advantages in terms of clinical efficacy and duration of benefits. The results obtained could contribute significantly to the development of more effective protocols and more precise management guidelines for patients with chronic omalgia, thus addressing existing controversies and improving clinical practice.

Conditions

Chronic Pain

Keywords

omalgia

Outcome Measures

Primary Outcomes (1)

• functional improvement between the intervention group and the control group measured by the absolute change in the Constant-Murley scale score

  Evaluate the efficacy of two PRP injections versus two injections of betamethasone with ropivacaine, both combined with a personalized exercise program, in the treatment of chronic shoulder pain secondary to rotator cuff tendinopathy.

  36 months

Study Arms (2)

platelet-rich plasma

EXPERIMENTAL

Two procedures are considered for obtaining an equivalent PRP formulation, with the aim of establishing a contingency plan for possible situations such as a shortage of specific materials (extraction tubes) or the unavailability of a dedicated clean room for preparation under open circuit conditions. PRP produced in-house, following the open technique, is prepared in a laminar flow cabinet within an environment that complies with the standards of asepsis and Good Manufacturing Practices required for this type of preparation.

Biological: Platelet-rich Plasma Local injection

betamethasone + ropivacaine

ACTIVE COMPARATOR

The control treatment consists of a mixture of 2 cc of betamethasone and 2 cc of ropivacaine.

Drug: betamethasone and Ropivacaine

Interventions

Platelet-rich Plasma Local injection BIOLOGICAL

Two procedures are considered for obtaining an equivalent PRP formulation, with the aim of establishing a contingency plan for possible situations such as a shortage of specific materials (extraction tubes) or the unavailability of a dedicated clean room for preparation under open circuit conditions. PRP produced in-house, following the open technique, is prepared in a laminar flow cabinet within an environment that complies with the standards of asepsis and Good Manufacturing Practices required for this type of preparation.

platelet-rich plasma

betamethasone and Ropivacaine DRUG

consists of a mixture of 2 cc of betamethasone and 2 cc of ropivacaine. To prepare it, 2 cc of betamethasone will be extracted from an ampoule of injectable solution using a sterile syringe (without attaching the needle) and mixed with 2 cc of ropivacaine.

betamethasone + ropivacaine

Eligibility Criteria

• Age: 35 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients between 35 and 75 years of age, both inclusive.
• Presence of pain in the affected shoulder for 3 or more months.
• Body Mass Index (BMI) values between 20 and 27 kg/m2, including both values.
• Confirmed diagnosis of chronic shoulder pain associated with rotator cuff tendinopathy, following an unfavorable response to standard treatment with analgesics and nonsteroidal anti-inflammatory drugs for 4-6 weeks.
• Patients who agree to participate in the study and sign the informed consent form.

You may not qualify if:

• Confirmed diagnosis of complete rotator cuff tear.
• Patients with systemic autoimmune rheumatic disease (connective tissue diseases and systemic necrotizing vasculitis).
• Patients with diabetes mellitus.
• Patients with hematological disorders (thrombopathy, thrombocytopenia, anemia with Hb\<9 g/dl).
• Patients undergoing treatment with intramuscular corticosteroids in the 3 months prior to the first administration of the trial treatment.
• Patients undergoing treatment with nonsteroidal anti-inflammatory drugs (more than 10 consecutive days at usual doses), opioids, or oral corticosteroids during the 15 days prior to treatment in the study.
• Patients with severe heart disease.
• Patients with active cancer or cancer diagnosed in the last 5 years.
• Patients who are taking a drug in clinical trials or have participated in any clinical trial (with an authorized or unauthorized product) in the 30 days prior to randomization.
• Patients with any physical, social, or psychological condition that, in the opinion of the investigators, may affect the patient's participation in the trial or the validity of the data obtained from their participation in it.
• Pregnant women.
• Breastfeeding women.
• Women of childbearing age\* who are unable or unwilling to use contraceptive methods with a failure rate of \<1% per year (bilateral tubal ligation, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the four-week treatment period.

Sponsors & Collaborators

• Biobizkaia Health Research Institute: lead

Study Sites (2)

Hospital Universitario Cruces

Barakaldo, Bizkaia, 48903, Spain

RECRUITING

Hospital Universitario Basurto

Bilbao, Bizkaia, 48013, Spain

NOT YET RECRUITING

MeSH Terms

Conditions

Chronic Pain

Interventions

Betamethasone; Ropivacaine

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Pregnadienetriols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 25, 2026
• First Posted: March 4, 2026
• Study Start: February 24, 2026
• Primary Completion (Estimated): February 1, 2029
• Study Completion (Estimated): April 1, 2029
• Last Updated: March 4, 2026

Record last verified: 2026-03

Locations

ES (2)